Shaida Khan
YOU?
Author Swipe
View article: Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study Open
Background: Zilucoplan, a peptide complement component 5 (C5) inhibitor, is self-administered as a subcutaneous (SC) injection, which offers an alternative to intravenous infusion of antibody-based complement C5 inhibitors. Objective: To e…
View article: Design and Implementation of a Brief, Self-Directed Course on Immunotherapy Best Practices for Neurology Trainees
Design and Implementation of a Brief, Self-Directed Course on Immunotherapy Best Practices for Neurology Trainees Open
OBJECTIVES To create and implement a brief, self-directed course on immunotherapy (IT) best practices for trainees on a neuroimmunology elective rotation. METHODS A working group of neurology faculty developed a curriculum covering the mec…
View article: Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension Open
Objectives To assess the safety, tolerability, and key pharmacodynamic effects of subcutaneous batoclimab, a fully human anti‐neonatal Fc receptor monoclonal antibody, in patients with generalized myasthenia gravis and anti‐acetylcholine r…
View article: P127. EFFECT OF LOWER EXTREMITY NERVE DECOMPRESSION IN PATIENTS WITH PAINFUL DIABETIC NEUROPATHY ON NARCOTIC USE AND ULCERATION RATES: A 10-YEAR FOLLOW-UP FROM THE PROSPECTIVE, CONTROLLED, RANDOMIZED, DOUBLE BLINDED, DNND I AND DNND II TRIALS
P127. EFFECT OF LOWER EXTREMITY NERVE DECOMPRESSION IN PATIENTS WITH PAINFUL DIABETIC NEUROPATHY ON NARCOTIC USE AND ULCERATION RATES: A 10-YEAR FOLLOW-UP FROM THE PROSPECTIVE, CONTROLLED, RANDOMIZED, DOUBLE BLINDED, DNND I AND DNND II TRIALS Open
PURPOSE: 10% of over 80 million American patients suffering from painful Diabetic Peripheral Neuropathy (DPN) rely on narcotics for pain relief. We present the 10-year follow-up from the Diabetic Neuropathy Nerve Decompression (DNND) I & I…
View article: Additional file 1 of Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy
Additional file 1 of Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy Open
Additional file 1. Named authors.
View article: Rapidly Progressive Paraneoplastic Neuropathy Associated with Renal Cell Carcinoma: A Case Report
Rapidly Progressive Paraneoplastic Neuropathy Associated with Renal Cell Carcinoma: A Case Report Open
This case highlights the rare occurrence of paraneoplastic neuropathy in renal cancer and emphasizes the importance of screening for malignancy in patients presenting with rapidly progressive multifocal neuropathy.
View article: Additional file 2 of Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy
Additional file 2 of Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy Open
Additional file 2. Co-investigators and acknowledgements.
View article: Autosomal Dominant ANO5-Related Disorder Associated With Myopathy and Gnathodiaphyseal Dysplasia
Autosomal Dominant ANO5-Related Disorder Associated With Myopathy and Gnathodiaphyseal Dysplasia Open
This report described the coexistence of muscle and bone phenotypes in the same patients with ANO5-related disorder. Our data challenge recent results that suggested complete dichotomy of these phenotypes and the proposed loss-of-function …
View article: Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Open
ClinicalTrials.gov Identifier: NCT03315130.
View article: 1099 HYPOGLOSSAL NERVE STIMULATION AS SALVAGE TREATMENT FOR OSA IN A PATIENT WITH REFRACTORY DEPRESSION
1099 HYPOGLOSSAL NERVE STIMULATION AS SALVAGE TREATMENT FOR OSA IN A PATIENT WITH REFRACTORY DEPRESSION Open
Hypoglossal nerve stimulation (HGNS) improves obstructive sleep apnea (OSA) in carefully selected patients. We present a patient with refractory psychiatric illness and severe OSA with intolerance to CPAP, oral appliance, and bariatric sur…
View article: 1108 REM Sleep Motor Dysregulation in Narcolepsy
1108 REM Sleep Motor Dysregulation in Narcolepsy Open
REM sleep without atonia (RSWA) occurs in up to 90% of narcolepsy patients. REM behavior disorder (RBD), however, is reported to occur in only 12% to 36% of patients with narcolepsy. Use of RSWA has been proposed as an additional marker fo…
View article: 1109 Hypoglossal Nerve Stimulation for Treatment of Patient with Severe Obstructive Sleep Apnea (OSA) Complicated by Severe Bruxism
1109 Hypoglossal Nerve Stimulation for Treatment of Patient with Severe Obstructive Sleep Apnea (OSA) Complicated by Severe Bruxism Open
Hypoglossal nerve stimulation (HGNS) has emerged as an effective treatment for obstructive sleep apnea (OSA). Bruxism is a sleep disorder that occurs in 8% of the general population. Safety of HGNS in OSA patients with bruxism has been unc…
View article: Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy
Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy Open
Background Duchenne muscular dystrophy ( DMD ) is frequently complicated by development of a cardiomyopathy. Despite significant medical advances provided to DMD patients over the past 2 decades, there remains a group of DMD patients who d…